Introduction
Valvular heart disease (VHD) contributes to cardiac dysfunction and cardiovascular morbidity and mortality, and affects a substantial subset of the global population (2-4% of adults aged >65 years) [1] . Cardiac valve conditions characterized by significant calcification of the leaflets are still among the most common cardiac valve lesions encountered in clinical practice. One such condition, aortic valve (AV) sclerosis, is the third-most common cardiovascular disease in the USA, and is predicted to have an incidence of 2.8% among patients aged ≥ 70 years [2] . Another condition, in which severe calcification and destruction of cardiac valves occurs, is rheumatic fever.
Rheumatic fever has an estimated worldwide incidence of between 5 and 30 million people and is responsible for >90,000 deaths annually [3] . It is estimated that >90% of all cases of mitral stenosis, both in developed and developing countries, are due to rheumatic fever [4, 5] . AV sclerosis and rheumatic fever account for the vast majority of calcific valve lesions seen in clinical practice.
Calcification can impair valve function and lead to cardiac dysfunction, necessitating valve replacement therapy. However, the exact reasons for AV and mitral valve (MV) calcification remain largely unknown. Although some risk factors (including older age, male sex, hypercholesterolemia, etc.) appear similar for AV calcification and atherosclerosis, as many as 50% of patients with calcific aortic stenosis do not have clinically significant atherosclerosis [6] . Meanwhile, less is known about the risk factors for MV calcification of various etiologies. In addition, no factors predicting valve calcification have been identified in clinical practice. In this study, we explore the potential risk factors for left-sided cardiac valve calcification via a retrospective analysis of data pertaining to 400 patients who received valve replacement surgery.
Materials and Methods

Patient Population
We screened all patients with VHD receiving single AV or MV surgery or combined AV and MV surgery between December 2009 and January 2013 at the First Affiliated Hospital of Nanjing Medical University, and found 400 qualifying patients. Patients who had received valve replacement with confirmed histopathological examinations were enrolled for this study. Patients who underwent valvuloplasty and traumatic valve repair without preexisting valve disease were excluded. The presence of valve leaflet calcification was confirmed by histopathological examinations. Data on baseline characteristics, potential etiology and surgical strategies were collected from electronic medical records. The VHD etiology and classification of valve lesions were identified based on the medical history, primary heart diseases and histopathological results recorded in the medical records according to the definition by Rajamannan et al. [7, 8] and Caira et al. [9] .
Measurement and Data Collection
Data collected from each patient's medical record included personal information, results of echocardiography, blood chemistry and pathological examination. Rheumatic, degenerative stenotic, degenerative nonstenotic and congenital causes, age and gender as well as serum levels of calcium (Ca 2+ ), alkaline phosphatase (ALP), retinol-binding protein (RBP), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglyceride (TG), lipoprotein a [Lp(a)], creatinine (Cr), blood urea nitrogen (BUN), uric acid (UA), gamma-glutamyl transferase (GGT), total bilirubin (TBIL) and direct bilirubin (DBIL) were stratified for purposes of regression analysis.
Statistical Analysis
Distributions of categorical variables were summarized as frequencies and percentages. Continuous data were summarized as mean ± standard deviation (SD). All categorical data were recorded as number (n), rate (%), odds ratio (OR) and 95% confidence interval (CI). Categorical data were analyzed using the Pearson χ 2 test. Continuous variables were analyzed with the Mann-Whitney U test, chosen as a conservative measure due to the challenges of determining true normality with a small dataset. Multivariate logistic regression analysis was used to assess for valve calcificationassociated factors. Variables entered into the model included etiology, age, gender and serum levels of Ca 2+ , ALP, RBP, TC, TG, LDL-C, Lp(a), Cr, BUN, UA, GGT, TBIL and DBIL. SAS for Windows v9.2 was used for all statistical analyses and p < 0.05 (2-sided) was considered statistically significant. Values denote n (%), except for age, which is expressed as mean ± SD. 1 ; table 2 ). In the rheumatic subgroup, the percentages of patients with simple mitral stenosis were higher in the control group than in the calcification group (46.6 vs. 27.6%; p = 0.024). The percentages of patients with combined mitral stenosis and aortic stenosis and regurgitation were higher in the calcification group (13.8 vs. 4.9%; p = 0.033). In the degenerative VHD group, aortic stenosis (76.9 vs. 7.7%; p = 0.000) and MV collapse (41.5 vs. 7.7%; p = 0.026) were the predominant lesion types in the calcification and noncalcification groups, respectively. Bicuspid AV stenosis was the predominant type in the congenital calcification group, but the percentage difference was not statistically significant when compared to the noncalcification group. Comparison of echocardiographic data before surgery showed that the aortic root diameter (AOD), left atrium diameter (LAD) and left ventricular (LV) end-diastolic diameter (LVDd), end-systolic diameter (LVDs), ejection fraction (LVEF) and fractional shortening (LVFS) were comparable between the 2 groups according to the different etiologies. However, in the rheumatic subgroup, the interventricular septal width (IVS) and LV posterior wall thickness (LVPW) in the calcification group were greater than in the noncalcification group ( table 3 ) . Hepatic and renal function blood indexes before surgery were also compared. The serum levels of alanine aminotransferase, aspartate aminotransferase, TBIL, DBIL, indirect bilirubin, TC, TG, albumin and Cr were comparable between the 2 groups. The BUN level was higher in the case group than in the control group in rheumatic patients (online suppl. table S1; see www.karger.com/doi/10.1159/000443203 for all online suppl. material). Coronary artery disease (CAD) is often accompanied by calcific aortic stenosis and mitral annulus calcification. The percentage of concomitant CAD was low in the rheumatic group. A higher percentage of CAD was observed in the congenital and degenerative groups, but the differences were not statistically significant between the 2 groups (online suppl. table S2).
Comparison of Groups for Risk Factors
Etiological factors including the presence of rheumatic, degenerative stenotic, degenerative nonstenotic and congenital VHD, age, gender and the levels of Ca 2+ , ALP, RBP, TC, TG, LDL-C, Lp(a), Cr, BUN, UA, GGT, TBIL and DBIL were identified as potential risk factors for valve calcification, and were stratified for logistic regression analysis. Multivariate analysis identified several statistically significant differences between the 2 groups. In an all-patient analysis group ( Infective Ca (n = 0) Infective Ctrl (n = 2) MVP 0 2 (100) n.a.
Figures in parentheses are percentages. AR = Aortic regurgitation; AS = aortic stenosis; AVC = aortic valve collapse; BAV = bicuspid aortic valve; Ca = case group; Ctrl = control group; MR = mitral regurgitation; MS = mitral stenosis; MVC = mitral valve collapse; MVM = mitral valve malformation; MVP = mitral valve perforation; n.a. = not applicable. tion. Ca 2+ levels of between 2.3 and 2.4 mmol/l showed significantly protective effects on valve calcification (OR 0.214; 95% CI 0.052-0.879; p = 0.032). Similarly, gender and serum levels of ALP and Cr were negatively associated, and age, RBP, LDL-C and DBIL positively associated with valve calcification, but the differences were not statistically significant in the all-patient group and in rheumatic patients. TC, TG, Lp(a), BUN and UA levels showed no association with valve calcification based on regression analysis.
Discussion
The major findings of our study include: (1) rheumatic VHD was the most common reason for cardiac valve replacement, (2) valve calcification occurred most often in the degenerative stenotic AV but not in nonstenotic valve lesions, (3) serum GGT and TBIL levels were positively correlated with cardiac valve calcification and serum Ca 2+ level was negatively correlated with rheumatic valve calcification. From this, we concluded that degenerative stenotic aortic lesion is an associated risk factor, that GGT and TBIL are positive predictors for the presence of cardiac valve calcification, that degenerative nonstenotic valve lesion is a negative predictor for valve calcification and that a normal serum Ca 2+ level is a negative predictor for rheumatic valve calcification.
Degenerative AV stenosis has become the most common type of VHD in developed countries [10] , and it often involves valvular calcification. Whether the AV is especially susceptible to calcification is not clear. Our results showed that the percentage of patients who underwent AV replacement in the calcification group was higher than that in the control group, which indicates AV susceptibility to calcification. A distribution assay of valve lesion types according to VHD etiology and logistic regression analysis indicated that calcific valve lesions occurred predominantly in the congenital and degenerative AV stenotic lesions, but that noncalcific valve lesions occurred in rheumatic and degenerative nonstenotic lesions, both in the MV and the AV. Degenerative stenotic valve lesion showed a strong relative risk correlated with valve calcification, but nonstenotic valve lesion was a negative predictor for valve calcification. Our results suggest that any tendency toward calcification of the AV is dependent on the VHD etiology and the type of valve lesion. It has been suggested that calcific AV stenosis and mitral annulus calcification have similar pathogenesis and share common risk factors with atherosclerotic vascular disease [11] . In this study, the percentage of concomitant CAD in the congenital and degenerative VHD groups was higher in the calcification group, indicating a trend of degenerative AV calcification accompanied by vascular sclerosis. However, the lower percentage of CAD in the rheumatic group indicates that the mechanism of rheumatic valve calcification is different from that of atherosclerotic calcification. In this study, we observed a significantly larger size of IVS and LVPW in the rheumatic calcification group, suggesting cardiohypertrophy associated with rheumatic valve calcification. Aortic stenotic lesion leads to an increased afterload and results in cardiohypertrophy, and mitral stenosis decreases the preload of the LV and results in normal or decreased LV size. Since there was a significant composition difference of valve lesion type between the rheumatic calcification and noncalcification groups, the higher aortic stenosis ratio and lower mitral stenosis ratio in the calcification group might have contributed to the increased LVPW.
Serum GGT level is related to many atherosclerotic risk factors, including hypertension, metabolic syndrome and diabetes [12] . GGT is also considered to be a marker for oxidative stress, which contributes to atherosclerosis. Atherosclerosis and calcific AV disease share some common risk factors and histopathological findings [13] . The controversial relationship between GGT and AV calcification was evaluated in 2 previous studies. In a cross-sectional study, Bozbas et al. [14] showed that serum GGT levels are increased in patients with calcific aortic stenosis and that these increases seem to occur in advanced, rather than milder, forms of calcific AV disease. In another study, Cappelli et al. [15] demonstrated the accumulation of GGT in lipid deposits and cellular elements of stenotic AVs and suggested a common mechanism of lesion shaping underlying both atherosclerosis and degenerative AV disease; however, they found a negative correlation between serum and tissue GGT levels and the severity of valve stenosis. In our study, we analyzed the correlation between GGT and both AV and MV calcification. We found that GGT was positively correlated with cardiac valve calcification regardless of valve type, suggesting that it is a risk factor for calcification and acts via a similar mechanism on both valve types. Further perspective cohort studies are needed to determine the exact role of GGT in heart valve calcification.
Bilirubin is a degradation product of heme and partially reflects the activity of heme oxygenase [16] . Bilirubin inhibits reactive oxygen species formation in vascular endothelium and serves as an antioxidant [17, 18] . In selected cohorts and general patient studies, it has been as-sociated with a decreased risk for cardiovascular events [19, 20] . Two recent cohort studies reported that the serum bilirubin level is inversely associated with coronary artery calcification by CT scanning, suggesting a protective effect of bilirubin on arterial sclerosis and calcification [21, 22] . There is no report of a relationship between serum TBIL and cardiac valve calcification. Contrary to the results of previous studies on coronary artery calcification, our data showed that an elevated serum TBIL level was positively associated with cardiac valve calcification. We speculate that a potential reason for the discrepancy between results is the differences in the study populations. Ruiz-Gaspa et al. [23] reported that bilirubin inhibits bone formation and that a high bilirubin level leads to osteoporosis in end-stage liver disease. As valve calcification is an ectopic mineralization and has similar mechanisms to bone formation [7, 9] , we speculate that bilirubin could not prevent the formation of valve calcification; however, a positive relationship between a higher bilirubin level and valve calcification might indicate a compensatory anticalcification effect of bilirubin. Contrary to bilirubin's role as a protective factor in the general population with cardiovascular risk factors, it appears to be a risk reporter for valve calcification in patients with cardiac valve disease.
Serum Ca 2+ and phosphorus abnormalities are associated with vascular and heart valve calcification [24, 25] . However, most of the data are from populations with advanced chronic renal disease concomitant with significant Ca
2+
-phosphorus metabolism dysfunction [26] . Two recent cross-sectional studies on patients with normal kidney function reported that elevated serum Ca 2+ , phosphorus and Ca 2+ -phosphorus product levels were the risk factors associated with coronary artery calcification [27, 28] . However, these 2 studies did not report the relation of serum Ca 2+ level to cardiac valve calcification.
Contrary to results on coronary artery calcification in previous studies, our data showed that serum Ca 2+ level is negatively correlated with rheumatic valve calcification, and that a serum Ca 2+ level of between 2.3 and 2.4 mmol/l had the lowest OR. The reason for the discrepancy between results is not clear. In our study population, kidney function was nearly normal, and the relationship was only found in rheumatic etiology; we thus speculate that the difference in VHD etiology between our subjects and those in the previous studies may have contributed to the discrepant results.
Limitations
This study has several limitations. First, the data were collected from a single center and the sample size was relatively small. Further, to maintain study power, the logistic regression analyses used were unconditional, meaning that the matching parameters were not specifically accounted for during the analysis of each risk factor. Finally, the small sample size precluded a multivariable analysis, meaning that independent risk factors were not demonstrated and confounding may therefore have been present.
